Staab, Thomas R.; Walter, Miriam; Mariotti Nesurini, Sonja - In: Health Economics Review 8 (2018) 23, pp. 1-11
Background: According to the AMNOG act, the German Federal Joint Committee (G-BA) determines the additional benefit of … appraisals of medicines that were withdrawn from the German market since the introduction of AMNOG in 2011. Methods: Medications …-BA (average 'no additional benefit' rating for all AMNOG products: 47%). Of the 22 medicines, 15 (68%) were recommended by at …